Related Experiment Videos
Fanconi syndrome after ifosfamide.
1Department of Paediatrics, John Radcliffe Hospital, Oxford, UK.
Cancer Chemotherapy and Pharmacology
|January 1, 1989
Summary
A child developed Fanconi syndrome after neuroblastoma treatment. This rare complication may be linked to ifosfamide chemotherapy.
Area of Science:
- Pediatric Oncology
- Nephrology
- Clinical Toxicology
Background:
- Neuroblastoma is a common pediatric cancer.
- Ifosfamide is a widely used chemotherapeutic agent for various cancers, including neuroblastoma.
- Fanconi syndrome is a generalized proximal tubular dysfunction affecting reabsorption in the kidneys.
Observation:
- A 2-year-old boy, successfully treated for neuroblastoma, presented with Fanconi syndrome.
- The onset of Fanconi syndrome occurred one year post-treatment.
- The patient's neuroblastoma treatment regimen included ifosfamide.
Findings:
- The case suggests a potential link between ifosfamide exposure and the development of Fanconi syndrome in pediatric patients.
- This represents a rare, delayed complication of ifosfamide therapy.
Implications:
- Clinicians should be vigilant for renal complications, such as Fanconi syndrome, in children treated with ifosfamide.
- Further research is warranted to elucidate the mechanisms and incidence of ifosfamide-induced Fanconi syndrome.
- This finding may inform long-term monitoring protocols for survivors of ifosfamide-treated cancers.